Literature DB >> 25412958

Clinicopathological and cellular signature of PAK1 in human bladder cancer.

Kai Huang1, Gang Chen, Jingfang Luo, Youyuan Zhang, Guoxiong Xu.   

Abstract

Bladder cancer (BC) is the ninth most common cancer and the 13th most common cause of cancer death. Although p21 protein-activated kinase (PAK) regulates cell growth, motility, and morphology, the expression and function of PAK1 associated with the clinicopathological and cellular signature of human BC are not clear. This study was to examine the expression of PAK1 in human BC, the association of PAK1 with clinicopathological features, and the effect of PAK1 on cell proliferation, migration, and invasion in BC cells. A total of 54 BC and 12 normal bladder tissue specimens were retrieved. Among 54 BC patients, 39 cases were superficial BC and 15 cases were invasive BC. Histological examination revealed 29 patients with low-grade and 25 patients with high-grade papillary urothelial carcinomas. Immunohistochemical staining showed that PAK1 was overexpressed in BC tissue compared with normal bladder tissue. The overexpression of PAK1 was significantly associated with tumor size, histological grade, and lymph node metastasis, but not with gender, age, clinical stage, tumor number, and recurrence. Furthermore, the cytoplasmic distribution of PAK1 was observed in BC cells. Knocking down of PAK1 using lentiviral transduction decreased BC cell proliferation, migration, and invasion. In conclusion, we demonstrated that the overexpression of PAK1 is closely associated with the clinicopathological features of BC, suggesting that PAK1 may play an important role in the development and progression of BC and may be a potential therapeutic target for the treatment of BC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25412958     DOI: 10.1007/s13277-014-2843-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  38 in total

Review 1.  Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations.

Authors:  Jeyanthy Eswaran; Da-Qiang Li; Anil Shah; Rakesh Kumar
Journal:  Clin Cancer Res       Date:  2012-05-17       Impact factor: 12.531

2.  p21-activated kinase 1 (PAK1) can promote ERK activation in a kinase-independent manner.

Authors:  Zhipeng Wang; Meng Fu; Lifeng Wang; Juanjuan Liu; Yuhua Li; Cord Brakebusch; Qibing Mei
Journal:  J Biol Chem       Date:  2013-05-07       Impact factor: 5.157

Review 3.  Epidemiology and risk factors of urothelial bladder cancer.

Authors:  Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan
Journal:  Eur Urol       Date:  2012-07-25       Impact factor: 20.096

Review 4.  Tracing PAKs from GI inflammation to cancer.

Authors:  Kyle Dammann; Vineeta Khare; Christoph Gasche
Journal:  Gut       Date:  2014-05-07       Impact factor: 23.059

5.  p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model.

Authors:  Hoi Yee Chow; Adrian M Jubb; Jennifer N Koch; Zahara M Jaffer; Dina Stepanova; David A Campbell; Sergio G Duron; Marie O'Farrell; Kathy Q Cai; Andres J P Klein-Szanto; J Silvio Gutkind; Klaus P Hoeflich; Jonathan Chernoff
Journal:  Cancer Res       Date:  2012-09-14       Impact factor: 12.701

6.  P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer.

Authors:  Masaaki Ito; Hiroyuki Nishiyama; Hiroaki Kawanishi; Shigeyuki Matsui; Parry Guilford; Anthony Reeve; Osamu Ogawa
Journal:  J Urol       Date:  2007-07-20       Impact factor: 7.450

7.  PAK signaling in cancer.

Authors:  Diana Zi Ye; Jeffrey Field
Journal:  Cell Logist       Date:  2012-04-01

Review 8.  p21-activated kinase 1: PAK'ed with potential.

Authors:  Christy C Ong; Adrian M Jubb; Wei Zhou; Peter M Haverty; Adrian L Harris; Marcia Belvin; Lori S Friedman; Hartmut Koeppen; Klaus P Hoeflich
Journal:  Oncotarget       Date:  2011-06

9.  Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.

Authors:  David J DeGraff; Peter E Clark; Justin M Cates; Hironobu Yamashita; Victoria L Robinson; Xiuping Yu; Mark E Smolkin; Sam S Chang; Michael S Cookson; Mary K Herrick; Shahrokh F Shariat; Gary D Steinberg; Henry F Frierson; Xue-Ru Wu; Dan Theodorescu; Robert J Matusik
Journal:  PLoS One       Date:  2012-05-10       Impact factor: 3.240

10.  Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway.

Authors:  Xingxing Wang; Lu Gui; Youyuan Zhang; Jihong Zhang; Jimin Shi; Guoxiong Xu
Journal:  Int J Oncol       Date:  2014-01-21       Impact factor: 5.650

View more
  4 in total

Review 1.  Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder.

Authors:  Vincent Sauzeau; Julien Beignet; Christian Bailly
Journal:  Biomedicines       Date:  2022-06-08

2.  Alteration of ASIC1 expression in clear cell renal cell carcinoma.

Authors:  Yan Li; Guoxiong Xu; Kai Huang; Jun Wang; Jihong Zhang; Jikai Liu; Zhanyu Wang; Gang Chen
Journal:  Onco Targets Ther       Date:  2015-08-14       Impact factor: 4.147

3.  Clinicopathological signature of p21-activated kinase 1 in prostate cancer and its regulation of proliferation and autophagy via the mTOR signaling pathway.

Authors:  Zhanyu Wang; Guojin Jia; Yan Li; Jikai Liu; Jinfang Luo; Jihong Zhang; Guoxiong Xu; Gang Chen
Journal:  Oncotarget       Date:  2017-04-04

4.  PAK1 as a Potential Therapeutic Target in Male Smokers with EGFR-Mutant Non-Small Cell Lung Cancer.

Authors:  Jae Heun Chung; Taehwa Kim; Yong Jung Kang; Seong Hoon Yoon; Yun Seong Kim; Sung Kwang Lee; Joo Hyung Son; Bongsoo Son; Do Hyung Kim
Journal:  Molecules       Date:  2020-11-27       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.